PERSPECTA

News from every angle

← Back to headlines

Guggenheim Raises Price Target for BeOne Medicines (ONC)

Guggenheim has increased its price target for BeOne Medicines (ONC) while maintaining a "Buy" rating on the stock. This adjustment reflects the firm's continued positive outlook on the pharmaceutical company.

14 May, 20:00 — 14 May, 20:00
PostShare

Sources

Showing 1 of 1 sources
YahooMostly Factual103d ago

Guggenheim Lifts BeOne Medicines (ONC) Price Target, Keeps Buy Rating

Read full article →

Related Stories

Par Pacific to Sell Laramie Energy Assets for $485 Million

53m ago

Multiple Company Executives Sell Significant Shares in Their Respective Firms

54m ago

Box Reports Strong Q2 2026 Revenue, Lifts Full-Year Outlook

59m ago

Franklin Templeton and Franklin Can Low Volatility ETF Announce Dividends

1h ago